Evidence map›Paper›PMID 40271310›Full record

ArticleCureus2025

Effective Management of Refractory Hepatic Hydrothorax With Hypertonic Glucose Pleurodesis.

Shuya Hashimoto, Toyoshi Yanagihara, Natsumi Kushima, Rei Sanai, Takato Ikeda, Naoki Hamada, Masaki Fujita

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuya HashimotoDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Toyoshi YanagiharaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Natsumi KushimaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Rei SanaiDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Takato IkedaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Naoki HamadaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Masaki FujitaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatic hydrothorax presents a significant challenge in advanced liver cirrhosis management, especially when conventional therapies fail. We report a case of a 66-year-old male with hepatitis C-related cirrhosis and advanced hepatocellular carcinoma who developed refractory left-sided hepatic hydrothorax despite maximal diuretic therapy. After failed talc pleurodesis, we employed an alternative approach using 50% glucose solution as a sclerosing agent. Following three sessions of hypertonic glucose pleurodesis, the patient achieved sustained resolution of pleural effusion with only minor, transient complications including hypotension and mild inflammatory response. Notably, he did not develop significant renal dysfunction or hepatic decompensation, complications commonly associated with conventional sclerosing agents in liver cirrhosis. Two-month follow-up imaging confirmed persistent pleural adhesion. This case highlights hypertonic glucose pleurodesis as a potentially safer alternative for managing refractory hepatic hydrothorax, particularly in patients unsuitable for transjugular intrahepatic portosystemic shunt or liver transplantation. However, further research is needed to establish optimal protocols, patient selection criteria, and long-term outcomes of this approach.

Indexed as

dyspneahepatic hydrothoraxhypertonic glucoseliver cirrhosispleurodesis

Identifiers

PMID40271310
PMCPMC12017293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.